Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of Tegileridine Fumarate for Inhibiting Hemodynamic Stress Response During Tracheal Intubation
NCT07749131Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegileridine in Hemodynamic stress response. Primary endpoint: 90% Effective Dose to suppress hemodynamic response of tracheal intubation. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tegileridine
03
Conditions
Hemodynamic stress response
Beyond the preview
Go deeper on NCT07749131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749131.